Collaborations & Services was Mannkind’s largest product and service line in fiscal 2025, bringing in $212.32M of $346.38M (61%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $15.60M | — | $102.34M | — | ||||||||
| Afrezza | $43.32M | $54.91M | $64.04M | — | ||||||||
| Collaborations & Services | $25.35M | $929.00K | $4.61M | $212.32M | ||||||||
| Afrezza Product Sales | — | $74.03M | $82.33M | $88.58M | ||||||||
| Product Sales | — | — | — | — | ||||||||
| Furoscix | — | — | — | $23.18M | ||||||||
| Developed Technology - On-Body Infusor | — | $19.12M | $18.29M | $16.37M | ||||||||
| V-Go | $12.93M | — | — | — | ||||||||
| Manufacturing Services | — | — | $7.10M | $1.60M | ||||||||
| Services | — | $929.00K | $4.61M | $4.33M | ||||||||
| Revenue - Other | — | — | — | — | ||||||||
| Total | $97.20M | $149.92M | $283.32M | $346.38M |
Mannkind brought in $346.38M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. Mannkind regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $283.32M. Collaborations & Services was the largest at $212.32M (61.3%), ahead of Afrezza Product Sales at $88.58M (25.6%) and Furoscix at $23.18M (6.7%). The other three lines brought in $22.30M combined.
Compared with fiscal 2024, Collaborations & Services grew fastest, up 4,503.6% to $212.32M, while Developed Technology - On-Body Infusor fell the most, down 10.5% to $16.37M.
Mannkind began breaking out Furoscix in fiscal 2025, Developed Technology - On-Body Infusor in fiscal 2023, Manufacturing Services in fiscal 2024 and Services in fiscal 2023. Mannkind stopped reporting Royalties ($102.34M in fiscal 2024), Afrezza ($64.04M in fiscal 2024) and V-Go ($12.93M in fiscal 2022) as separate lines.
Ut Csa was Mannkind’s largest revenue line in fiscal 2025, bringing in $192.57M of $320.69M (60%).
| Related and Nonrelated Parties | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Ut Csa | $101.31M | $180.29M | $192.57M |
| United Therapeutics Corporation | $71.98M | $102.34M | $128.12M |
| Total | $173.29M | $282.62M | $320.69M |
Mannkind brought in $320.69M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $346.38M it reports by product and service, so these revenue lines do not cover all of its revenue. Ut Csa was the largest at $192.57M (60.0%), ahead of United Therapeutics Corporation at $128.12M (40.0%).
Compared with fiscal 2024, United Therapeutics Corporation grew 25.2% to $128.12M and Ut Csa grew 6.8% to $192.57M.
Mannkind (MNKD) reports its revenue by product and service and by related and nonrelated parties. In fiscal 2025, Collaborations & Services was its largest product and service line, bringing in $212.32M (61.3% of the total), followed by Afrezza Product Sales at $88.58M (25.6%).
Collaborations & Services was Mannkind's largest product and service line in fiscal 2025, bringing in $212.32M, or 61.3% of the $346.38M total across its six product and service lines.
Ut Csa was Mannkind's largest revenue line in fiscal 2025, bringing in $192.57M, or 60.0% of the $320.69M total across its two revenue lines.
United Therapeutics Corporation grew faster than Ut Csa in fiscal 2025, up 25.2% from $102.34M to $128.12M. Ut Csa grew 6.8% to $192.57M.
Every figure comes from Mannkind's annual financial filings, as reported. Each line keeps the name Mannkind gives it, and years follow its fiscal calendar.
Mannkind's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.